Long-Term Predictors of Mortality After Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents
William McLeish Wilson, Nick Andrianopoulos, David Clark, Stephen James Duffy, Angela Brennan, Iwan Harries, Gishel New, Martin Sebastian, Philippa Loane, Christopher Reid, Andrew Edward Ajani
AMERICAN JOURNAL OF CARDIOLOGY | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | Published : 2011
The aim was to examine timing, causes, and predictors of death during long-term follow-up after contemporary percutaneous coronary intervention (PCI) using a large multicenter Australian registry. The cohort consisted of 10,682 consecutive patients from the Melbourne Interventional Group registry undergoing PCI (February 2004 through November 2009). For the first time in Australia, long-term mortality rates of a PCI cohort were defined by linkage to the National Death Index database. The cohort (mean age 64 ± 12 years) comprised 75% men, 24% diabetics, 59% with multivessel disease, 4.4% with renal failure, 25% with ST-elevation myocardial infarction (STEMI), 2.5% with cardiogenic shock, and ..View full abstract
The Melbourne Interventional Group acknowledges unrestricted educational grant funding from Abbott Vascular, Abbott Australasia Pty Ltd, Pharmaceuticals, Nutritionals and EAS, NSW, Australia, Astra-Zeneca, NSW, Australia, Biotronik, NSW, Australia, Boston-Scientific, NSW, Australia, Bristol-Myers Squibb, Victoria, Australia, CSL, Victoria, Australia, Johnson & Johnson, NSW, Australia, Medtronic, Melbourne, Australia, Pfizer, NSW, Australia, Schering-Plough, NSW, Australia, Sanofi-Aventis, NSW, Australia, Servier, Victoria, Australia. Dr. Dufty's work is supported by a grant from the National Health and Medical Research Council of Australia.